Volume 47 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology.
1. 2. Introduction: Thrombosis and Cardiovascular Disease 2. 3. The Blood Coagulation 3. 4. Markers of Hemostatic Activation 4. 5. F1+2 in Cardiovascular Disease 5. 6. How Can Circulating Levels of F1+2 Be Modulated? 6. 7. Pathophysiological Aspects of Other Prothrombin Fragments 7. 8. Conclusions 8. Acknowledgments 9. Carbamylated LDL 10. 1. Abstract 11. 2. Atherosclerosis in Kidney Disease 12. 3. Chronic Uremia-Induced Atherosclerosis 13. 4. Modified LDLs in Atherosclerosis 14. 5. Uremic Toxins and Protein Carbamylation 15. 6. Plasma Protein Carbamylation and Atherosclerosis 16. 7. LDL Carbamylation: Initial Observations 17. 8. Induction of Proliferation and Death of Cultured Endothelial Cells by cLDL 18. 9. Acceleration of Monocyte Adhesion to Endothelial Cells by cLDL 19. 10. Endothelial cLDL Receptors 20. 11. Effects of cLDL on Cultured Smooth-Muscle Cells 21. 12. In Vivo Properties of cLDL 22. 13. cLDL Assays 23. 14. Human Studies of cLDL 24. 15. Autoantibody to cLDL and Other Modified LDLs 25. 16. Double Modified LDLs 26. 17. Perspectives of Anti-cLDL Therapy 27. 18. Conclusion 28. Cocaine in Acute Myocardial Infarction 29. 1. Abstract 30. 2. Structure and Metabolism of Cocaine 31. 3. Epidemiology of Cocaine Abuse 32. 4. Cocaine Testing 33. 5. Toxicity of Cocaine Abuse 34. 6. Cocaine and Chest Pain 35. 7. Should Cocaine Use Be Screened in Patients with Acute Myocardial Infarctions? 36. 8. Conclusions 37. EGFR and KRAS in Colorectal Cancer 38. 1. Abstract 39. 2. Introduction 40. 3. EGFR Signal Transduction 41. 4. Monoclonal Antibodies Targeting EGFR 42. 5. Landmark Clinical Trials in the Pre-KRAS Era 43. 6. Predictive Value of EGFR 44. 7. Biology of RAS 45. 8. Prognostic Relevance of KRAS Mutations in Colorectal Cancer 46. 9. Predictive Role of KRAS Status in Colorectal Cancer 47. 10. Testing for KRAS Status 48. 11. BRAF in Colorectal Cancer 49. 12. Predictive Role of BRAF in Colorectal Cancer 50. 13. Alternate Predictive Biomarkers for anti-EGFR Therapies in Colorectal Cancer 51. 14. Future Therapeutic Strategies in Colorectal Cancer 52. 15. Conclusion 53. Prostaglandin EP Receptors and Their Roles in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract 54. 1. Abstract 55. 2. Introduction 56. 3. Gastric Protection 57. 4. Esophageal Protection 58. 5. Duodenal Protection and HCO3− Stimulation 59. 6. Intestinal Protection 60. 7. Healing-Promoting Action 61. 8. Summary and Future Prospects 62. Acknowledgments 63. Advances in Pancreatic Cancer Detection 64. 1. Abstract 65. 2. Introduction 66. 3. Conventional Markers 67. 4. Candidates in Biomarker Discovery 68. 5. Therapy-Related Biomarkers 69. 6. Genomics/Transcriptomics/Proteomics 70. 7. Conclusions 71. Acknowledgments 72. Urine Peptidomics for Clinical Biomarker Discovery 73. 1. Abstract 74. 2. Introduction 75. 3. Urine Peptidome is a Rich Source of Peptides of Diversified Protein Origins 76. 4. Quantitative Urine Peptidomics for Biomarker Discovery 77. 5. Urine Sample Handling and Storage 78. 6. Do “Housekeeping Peptides” Exist in Urine Peptidome? 79. 7. To Pool or Not Pool, Practical Considerations of Benefits, Risks and Biases 80. 8. Multiple Hypothesis Testing, False Discovery, and Bootstrapping Analysis 81. 9. Exploration of Urine Peptide Biomarkers as Predictors of Drug Response 82. 10. Urine Peptidome Proteolytic Degradation Patterns Reflecting Pathophysiology 83. Acknowledgments
Volume 47 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology.
1. 2. Introduction: Thrombosis and Cardiovascular Disease 2. 3. The Blood Coagulation 3. 4. Markers of Hemostatic Activation 4. 5. F1+2 in Cardiovascular Disease 5. 6. How Can Circulating Levels of F1+2 Be Modulated? 6. 7. Pathophysiological Aspects of Other Prothrombin Fragments 7. 8. Conclusions 8. Acknowledgments 9. Carbamylated LDL 10. 1. Abstract 11. 2. Atherosclerosis in Kidney Disease 12. 3. Chronic Uremia-Induced Atherosclerosis 13. 4. Modified LDLs in Atherosclerosis 14. 5. Uremic Toxins and Protein Carbamylation 15. 6. Plasma Protein Carbamylation and Atherosclerosis 16. 7. LDL Carbamylation: Initial Observations 17. 8. Induction of Proliferation and Death of Cultured Endothelial Cells by cLDL 18. 9. Acceleration of Monocyte Adhesion to Endothelial Cells by cLDL 19. 10. Endothelial cLDL Receptors 20. 11. Effects of cLDL on Cultured Smooth-Muscle Cells 21. 12. In Vivo Properties of cLDL 22. 13. cLDL Assays 23. 14. Human Studies of cLDL 24. 15. Autoantibody to cLDL and Other Modified LDLs 25. 16. Double Modified LDLs 26. 17. Perspectives of Anti-cLDL Therapy 27. 18. Conclusion 28. Cocaine in Acute Myocardial Infarction 29. 1. Abstract 30. 2. Structure and Metabolism of Cocaine 31. 3. Epidemiology of Cocaine Abuse 32. 4. Cocaine Testing 33. 5. Toxicity of Cocaine Abuse 34. 6. Cocaine and Chest Pain 35. 7. Should Cocaine Use Be Screened in Patients with Acute Myocardial Infarctions? 36. 8. Conclusions 37. EGFR and KRAS in Colorectal Cancer 38. 1. Abstract 39. 2. Introduction 40. 3. EGFR Signal Transduction 41. 4. Monoclonal Antibodies Targeting EGFR 42. 5. Landmark Clinical Trials in the Pre-KRAS Era 43. 6. Predictive Value of EGFR 44. 7. Biology of RAS 45. 8. Prognostic Relevance of KRAS Mutations in Colorectal Cancer 46. 9. Predictive Role of KRAS Status in Colorectal Cancer 47. 10. Testing for KRAS Status 48. 11. BRAF in Colorectal Cancer 49. 12. Predictive Role of BRAF in Colorectal Cancer 50. 13. Alternate Predictive Biomarkers for anti-EGFR Therapies in Colorectal Cancer 51. 14. Future Therapeutic Strategies in Colorectal Cancer 52. 15. Conclusion 53. Prostaglandin EP Receptors and Their Roles in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract 54. 1. Abstract 55. 2. Introduction 56. 3. Gastric Protection 57. 4. Esophageal Protection 58. 5. Duodenal Protection and HCO3− Stimulation 59. 6. Intestinal Protection 60. 7. Healing-Promoting Action 61. 8. Summary and Future Prospects 62. Acknowledgments 63. Advances in Pancreatic Cancer Detection 64. 1. Abstract 65. 2. Introduction 66. 3. Conventional Markers 67. 4. Candidates in Biomarker Discovery 68. 5. Therapy-Related Biomarkers 69. 6. Genomics/Transcriptomics/Proteomics 70. 7. Conclusions 71. Acknowledgments 72. Urine Peptidomics for Clinical Biomarker Discovery 73. 1. Abstract 74. 2. Introduction 75. 3. Urine Peptidome is a Rich Source of Peptides of Diversified Protein Origins 76. 4. Quantitative Urine Peptidomics for Biomarker Discovery 77. 5. Urine Sample Handling and Storage 78. 6. Do “Housekeeping Peptides” Exist in Urine Peptidome? 79. 7. To Pool or Not Pool, Practical Considerations of Benefits, Risks and Biases 80. 8. Multiple Hypothesis Testing, False Discovery, and Bootstrapping Analysis 81. 9. Exploration of Urine Peptide Biomarkers as Predictors of Drug Response 82. 10. Urine Peptidome Proteolytic Degradation Patterns Reflecting Pathophysiology 83. Acknowledgments
